-
Spectrum Pharma Appoints Kurt Gustafson As EVP, CFO And Principal Accounting Officer
6/5/2013
|
|
|
-
Halozyme Therapeutics Reports Results From Phase 1b Trial Of PEGPH20 In Combination With Gemcitabine
6/3/2013
|
|
|
-
Halozyme Therapeutics Appoints David Ramsay As CFO
5/23/2013
|
-
Baxter Receives Marketing Authorization For HyQvia In European Union
5/21/2013
|
|
|
-
Barclays Capital Is Cutting Halozyme Therapeutics, Inc. (HALO) FY14 Estimate To -0.67 From -0.55
5/9/2013
|
-
Barclays Capital Is Lowering Halozyme Therapeutics, Inc. (HALO) FY13 Estimate To -0.72 From -0.60
5/9/2013
|
-
Halozyme Therapeutics Posts Q1 Loss Per Share Of $0.17 Vs. Loss $0.14 Year Ago
5/8/2013
|